Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using…
Planegg/Martinsried, June 27, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on…
GEN2’s dose-escalation trial, GVO-1102, will establish the Recommended Phase 2 Dose (RP2D), followed immediately by an expansion phase into 3…
GRAND RAPIDS, Mich., June 26, 2024 /PRNewswire/ -- On June 24, 2024, Rep. Hillary Scholten (MI-03) joined members of the National Blood…
Results of an international multi-center study to evaluate the accuracy of the ClarityDX Prostate screening test are now available to…
Halifax, Nova Scotia--(Newsfile Corp. - June 26, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")…
Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic CancerLOS ALTOS, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc.…
PALO ALTO, CA / ACCESSWIRE / June 26, 2024 / Bioz, Inc., a pioneer in AI-driven research solutions, is delighted…
NEW YORK, June 25, 2024 /PRNewswire/ -- The Informatics Technology for Cancer Research (ITCR) program of the NIH National Cancer…
INDIANAPOLIS, June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow…